Earnings Preview For Intra-Cellular Therapies

Intra-Cellular Therapies (NASDAQ:ITCI) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Intra-Cellular Therapies to report an earnings per share (EPS) of $-0.19.

The market awaits Intra-Cellular Therapies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Performance in Previous Earnings

During the last quarter, the company reported an EPS beat by $0.03, leading to a 1.07% increase in the share price on the subsequent day.

Here's a look at Intra-Cellular Therapies's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

-0.19

-0.33

-0.43

-0.56

EPS Actual

-0.16

-0.16

-0.30

-0.25

Price Change %

1.0%

-6.0%

-2.0%

5.0%

Intra-Cellular Therapies Share Price Analysis

Shares of Intra-Cellular Therapies were trading at $76.82 as of October 28. Over the last 52-week period, shares are up 52.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Take on Intra-Cellular Therapies

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Intra-Cellular Therapies.

A total of 12 analyst ratings have been received for Intra-Cellular Therapies, with the consensus rating being Outperform. The average one-year price target stands at $102.08, suggesting a potential 32.88% upside.

Peer Ratings ...